5
ESMO-MCBS v1.1
Scorecard version: 1
Indication details
- Tumour Type
- Thoracic Malignancies
- Tumour Sub-type
- Squamous or non-squamous non-small-cell lung cancer
- Tumour stage
- Metastatic
- Control Arm
- Docetaxel
- Treatment Setting
- Squamous or non-squamous stage IIIB or IV patients who had previously received one or two chemotherapy regimes
- Trial Name
- OAK
Primary Outcome(s)
- Primary Outcome(s)
- OS
- Form(s)
- Form 2a
Outcome Data
- OS Control
- 9.6 months
- OS Gain
- 4.2 months
- OS HR
- 0.73 (0.62-0.87)
- Toxicity Comment
- Improved toxicity profile
Final Score (after adjustments)
- Preliminary non-curative score
- 4
- Toxicity adjustment
- 1+
- Final non-curative Score
- 5
- Release date
- 15.05.2019
- Last update
- 16.03.2020
DFS, disease-free survival; DoR, duration of response; EFS, event-free survival; HR, hazard ratio; iDFS, invasive disease-free survival; ITT, intention to treat; mPFS, median progression-free survival; ORR, overall response rate; OS, overall survival; pCR, pathologic complete response/remission; PFS, progression-free survival; QoL, quality of life; RFS, relapse-free survival; RR, response rate